Michael is a biotechnology executive, company builder, and scientific founder whose experience spans precision diagnostics, company formation, translational medicine, clinical development, commercialization, and strategic operations.
Build biotechnology companies that transform scientific innovation into products, organizations, and clinical impact.
Michael's career has been defined by a recurring question: how should this biotechnology company be built?
That question has led him across regulated diagnostic development, company formation and technology licensing, first-in-human clinical programs, and integrated scientific and corporate strategy.
Attenuated Technologies is his independent operating practice for selected executive appointments, strategic engagements, and company-building work.
Biotechnology company building is rarely contained within a single function. Scientific strategy, organizational design, translational execution, technology, capital readiness, and product decisions shape one another.
Attenuated Technologies provides an enduring operating practice for that work, with Michael serving as Founder & Principal.
At SEngine Precision Medicine, Michael helped translate a functional oncology platform into the CLIA-certified P.A.R.I.S. test and supported personalized testing for more than 100 cancer patients.
As Founder & Chief Scientist of Brahma Therapeutics, he negotiated foundational technology licenses and built a de novo peptide platform from concept through proof of concept and strategic readiness.
At CREATE Medicines, formerly Myeloid Therapeutics, he led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
Through Attenuated Technologies, he serves as Interim CSO/CBO to MultiOmics, leading scientific development, operations, and corporate strategy for an AI-native precision-diagnostics company focused on early breast-cancer detection.
Representative engagements on this site provide evidence of Michael's broader career record.
Michael's work connects scientific discovery, translational research, engineering, diagnostics, clinical development, and commercialization.
He approaches artificial intelligence as a strategic capability: identifying high-value applications, defining intended outcomes, and guiding adoption by technical teams rather than presenting himself as the primary software implementer.
Michael's leadership approach emphasizes clear decision rights, explicit assumptions, evidence-based reasoning, and accountable execution.
He builds systems that help scientific, technical, clinical, and business teams work across boundaries and execute against shared objectives.
Michael founded Attenuated Technologies in 2025 as the practice through which he builds biotechnology organizations over time.
The practice remains centered on ambitious science, thoughtful engineering, and the organizational work required to create durable companies.